everolimus

01/15/2014 - "Notably, administration of the mTOR inhibitor everolimus during periods of elevated mTOR improved survival in tumor-bearing mice. "
09/27/2007 - "The probability of survival of everolimus group was significantly greater than the observed in a historical cohort of 14 liver recipients with comparable tumors who did not receive everolimus (100%, 90%, 72% vs. 50%, 29%, 14%) at 6, 12, and 24 months, respectively (HR=4.6, 95% confidence interval: 1.3-16.4; P=0.008). "
02/05/2013 - "This study provides Class III evidence that everolimus, titrated to trough serum levels of 5-15 ng/mL, was effective in reducing tumor size in patients with SEGA secondary to TSC for a median of 34 months."
01/01/2015 - "The results demonstrated that everolimus enhanced the therapeutic efficacy of TACE in inhibiting cell proliferation, promoting apoptosis and inhibiting tube formation of endothelial cells by blocking the Akt/mTOR signaling pathway in vitro and inhibiting tumor growth and neoangiogenesis in vivo. "
10/01/2012 - "However, inhibitors of this pathway such as Rad001 have not shown therapeutic efficacy as a single agent for this cancer. "

10/01/2010 - "In oncology, everolimus has been proven effective for the management of treatment-resistant renal cell carcinoma. "
01/01/2012 - "We report an unexpectedly high efficacy of everolimus as a third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. "
11/05/2015 - "This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. "
11/01/2013 - "The aim of the study was to assess the safety and efficacy of everolimus therapy for advanced renal cell carcinoma in Japanese patients receiving real-world care. "
10/01/2013 - "This study evaluates the safety and efficacy of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC). "

01/01/2013 - "Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer."
09/01/2012 - "Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells."
01/01/2014 - "In clinical trials, the addition of everolimus to hormonal treatment or anti-HER2 treatment improved the outcomes of breast cancer patients. "
08/01/2013 - "Given the efficacy of everolimus in HR-positive metastatic breast cancer, it is crucial for physicians to recognize toxicities related to everolimus and start timely interventions. "
10/01/2015 - "Monthly transition probabilities were estimated based on the BOLERO-2 (Breast cancer trials of OraL EveROlimus-2) data and network meta-analyses. "

01/01/2014 - "The mTOR inhibitor everolimus has shown promising results in some but not all neuroendocrine tumors. "
02/01/2014 - "Medical management of pancreatic neuroendocrine tumors has recently been improved by new molecules of which the mTOR inhibitor everolimus. "
09/01/2012 - "Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors."
02/01/2014 - "Everolimus has demonstrated efficacy in unresectable and progressive pancreatic neuroendocrine tumors, by doubling the median progression free survival (11 versus 4.6 months), with a median time of exposure to everolimus of nine months. "
12/01/2013 - "Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate."

03/01/2013 - "Everolimus significantly improved progression-free survival among patients with pNET in the phase III RADIANT-3 study. "
03/01/2011 - "Since last year, there has been a significant advance in the management of PNET, after reported data confirmed the efficacy of everolimus, an mTOR inhibitor, in patients with advanced disease. "
11/01/2014 - "Although everolimus-based phase II/III trials have improved progression-free survival for pNET, its use has not impacted on prolonging overall survival. "
09/01/2012 - "Based on review of the available literature, everolimus is a safe and effective treatment option for patients with low- to intermediate-grade, unresectable or metastatic pNET that have progressed on prior therapies. "
01/01/2012 - "Everolimus was again associated with improvement in PFS compared to placebo and it has been approved by the FDA for patients with progressive pNET. "